NEUROTECH INTERNATIONAL LIMITED - Announcements

7.69%

1.4¢

Market Cap $14.69M

Healthcare Biotechnology

Neurotech International Limited is an Australia-based clinical-stage biopharmaceutical... Neurotech International Limited is an Australia-based clinical-stage biopharmaceutical development company. The Company is focused predominately on pediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. It has completed a Phase II/III randomized, double-blind, placebo-controlled clinical trial in autism spectrum disorder (ASD) with clinically significant benefits reported across a number of clinically validated measures and safety. In addition, it has completed and reported significant and clinically meaningful Phase I/II trials in ASD and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. NTI164 is being developed as a therapeutic drug product for a range of neurological disorders in children where neuroinflammation is involved.More

HELPING PATIENTS ON THEIR JOURNEY TO BETTER HEALTH

Little Green Pharma (ASX:LGP) to benefit as Denmark commits to cannabis pilot program.

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

NTI	Appendix 4E & Annual Report to shareholders	PRICE SENSITIVE	29/08/25	2.03MB	Share
NTI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/07/25	380.56KB	Share
NTI	Positive Human PK Study Results for NTI164	PRICE SENSITIVE	02/06/25	123.18KB	Share
NTI	NTI164 Preclinical Toxicology Studies Update	PRICE SENSITIVE	05/05/25	112.86KB	Share
NTI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/04/25	314.41KB	Share
NTI	Appendix 4D and Half Year Accounts	PRICE SENSITIVE	27/02/25	1006.37KB	Share
NTI	Positive Opinion on OMPD for NTI164 in Europe	PRICE SENSITIVE	27/02/25	119.43KB	Share
NTI	NTI Signs Development Agreement for Cannabinoid Therapies	PRICE SENSITIVE	13/02/25	127.25KB	Share
NTI	Neurotech Receives $2.44 Million R&D Tax Incentive Refund	PRICE SENSITIVE	31/01/25	134.52KB	Share
NTI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/01/25	349.64KB	Share
NTI	Neurotech Receives US ODD in Rett Syndrome	PRICE SENSITIVE	26/11/24	127.66KB	Share
NTI	NTI Receives Ethics Approval to Commence Human PK Study	PRICE SENSITIVE	25/11/24	129.34KB	Share
NTI	Positive Genomic Effects of NTI164 in PANDAS/PANS Patients	PRICE SENSITIVE	15/11/24	211KB	Share
NTI	Neurotech Appoints Dr Anthony Filippis as MD/CEO	PRICE SENSITIVE	11/11/24	118.54KB	Share
NTI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	23/10/24	410.52KB	Share
NTI	US FDA Response to Orphan Drug Request in PANDAS/PANS	PRICE SENSITIVE	04/10/24	103.42KB	Share
NTI	NTI164 Reverses Immune Dysregulation in PANDAS/PANS Children	PRICE SENSITIVE	09/09/24	160.17KB	Share
NTI	Appendix 4E & Annual Report to shareholders	PRICE SENSITIVE	26/08/24	8.99MB	Share
NTI	Neurotech Global Partnering and Registration Strategy	PRICE SENSITIVE	12/08/24	185.09KB	Share
NTI	Further Significant Improvement in Rett Syndrome Patients	PRICE SENSITIVE	31/07/24	297.53KB	Share
NTI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	25/07/24	671.56KB	Share
NTI	Phase II/III autism trial shows further benefits	PRICE SENSITIVE	18/07/24	194.28KB	Share
NTI	Significant improvement in Autism patients at 12 weeks	PRICE SENSITIVE	10/07/24	347.14KB	Share
NTI	Phase I/II Autism Patients Meet 2 Years of NTI164 Treatment	PRICE SENSITIVE	17/06/24	190.62KB	Share
NTI	Further clinical benefit at 52 weeks in PANDAS/PANS patients	PRICE SENSITIVE	06/06/24	190.18KB	Share
NTI	Rett Syndrome Phase I/II trial shows significant benefits	PRICE SENSITIVE	06/05/24	593.85KB	Share
NTI	Trading Halt	PRICE SENSITIVE	03/05/24	140.26KB	Share
NTI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	23/04/24	445.81KB	Share
NTI	Neurotech Completes $10 Million Capital Raise	PRICE SENSITIVE	17/04/24	193.4KB	Share
NTI	Positive Top-Line Rett Syndrome Clinical Trial Results	PRICE SENSITIVE	17/04/24	200.12KB	Share
NTI	Phase II/III ASD Trial Successfully Meets Primary Endpoint	PRICE SENSITIVE	17/04/24	361.07KB	Share
NTI	Trading Halt	PRICE SENSITIVE	15/04/24	141.44KB	Share
NTI	Last Patient Completes Treatment in NTIASD2 Clinical Trial	PRICE SENSITIVE	10/04/24	183.31KB	Share
NTI	Rett Syndrome Patients to Receive NTI164 for 52 Weeks	PRICE SENSITIVE	13/03/24	180.94KB	Share
NTI	Appendix 4D and Half Year Accounts	PRICE SENSITIVE	27/02/24	814.41KB	Share
NTI	PANDAS/PANS Patients Show Continued Clinical Improvement	PRICE SENSITIVE	21/02/24	325.1KB	Share
NTI	Neurotech Receives Additional HREC Approval in Autism	PRICE SENSITIVE	13/02/24	114.1KB	Share
NTI	NTI Receives HREC Approval for Cerebral Palsy Trial	PRICE SENSITIVE	29/01/24	179.92KB	Share
NTI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	24/01/24	583.12KB	Share
NTI	Phase II/III Autism Clinical Trial Completes Recruitment	PRICE SENSITIVE	19/12/23	178.77KB	Share
NTI	HREC Approval to Extend Phase II/III ASD Trial to Adults	PRICE SENSITIVE	04/12/23	175.52KB	Share
NTI	Neurotech Receives $3.17 Million R&D Tax Incentive Refund	PRICE SENSITIVE	14/11/23	105.98KB	Share
NTI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	27/10/23	396.35KB	Share
NTI	Phase I/II PANDAS/PANS Clinical Trial Meets Primary Endpoint	PRICE SENSITIVE	06/10/23	202.18KB	Share
NTI	Trading Halt	PRICE SENSITIVE	04/10/23	503.7KB	Share
NTI	Completion of Patient Recruitment in NTIRTT1 Clinical Trial	PRICE SENSITIVE	26/09/23	186.34KB	Share
NTI	Last Patient Completes Treatment in NTIPANS1 Clinical Trial	PRICE SENSITIVE	31/08/23	141.88KB	Share
NTI	Appendix 4E & Annual Report	PRICE SENSITIVE	30/08/23	1.16MB	Share
NTI	First Patient Treated in Rett Syndrome Clinical Trial	PRICE SENSITIVE	01/08/23	181.29KB	Share
NTI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	26/07/23	321.97KB	Share
NTI	NTI Receives HREC Approval for Rett Syndrome Clinical Trial	PRICE SENSITIVE	10/07/23	213.2KB	Share
NTI	NTI Granted 2 Year Extension of Treatment for ASD Patients	PRICE SENSITIVE	31/05/23	188.33KB	Share
NTI	NTI granted HREC Approval for PANDAS/PANS Trial Extension	PRICE SENSITIVE	30/05/23	178.8KB	Share
NTI	NTI Completes Recruitment in PANDAS/PANS Clinical Trial	PRICE SENSITIVE	03/05/23	138.62KB	Share
NTI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	27/04/23	335.94KB	Share
NTI	NTI to Launch Phase II Clinical Trial in Rett Syndrome	PRICE SENSITIVE	20/03/23	199.04KB	Share
NTI	Phase I/II ASD Clinical Trials Results at 52 Weeks	PRICE SENSITIVE	17/03/23	360.83KB	Share
NTI	Trading Halt	PRICE SENSITIVE	15/03/23	499.87KB	Share
NTI	Appendix 4D and Half Year Accounts	PRICE SENSITIVE	28/02/23	476.67KB	Share
NTI	First Patient Treated in Phase I/II PANDAS/PANS Trial	PRICE SENSITIVE	16/02/23	170.25KB	Share
NTI	Approval for Additional Phase I/II ASD Trial Extension	PRICE SENSITIVE	14/02/23	170.33KB	Share
NTI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/01/23	711.15KB	Share
NTI	HREC Approval for Phase I/II PANDAS/PANS Clinical Trial	PRICE SENSITIVE	27/01/23	207.61KB	Share
NTI	NTI Granted FDA Pre-IND Meeting for NTI164 in ASD	PRICE SENSITIVE	19/01/23	173.92KB	Share
NTI	Disclosure Document	PRICE SENSITIVE	22/12/22	303.07KB	Share
NTI	Commencement of Phase II/III ASD Clinical Trial	PRICE SENSITIVE	19/12/22	179.16KB	Share
NTI	NTI Receives HREC/TGA Approval for Phase II/III ASD Trial	PRICE SENSITIVE	17/11/22	271.47KB	Share
NTI	Neurotech Receives $1.2M R&D Tax Rebate	PRICE SENSITIVE	31/10/22	133.45KB	Share
NTI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/10/22	340.9KB	Share
NTI	Reinstatement to Quotation	PRICE SENSITIVE	28/10/22	409.65KB	Share
NTI	Neurotech Completes $9.0M Placement	PRICE SENSITIVE	28/10/22	280.19KB	Share
NTI	Suspension From Official Quotation	PRICE SENSITIVE	27/10/22	585.19KB	Share
NTI	20 Week Data Shows Significant Improvement For ASD Children	PRICE SENSITIVE	26/10/22	465.94KB	Share
NTI	Trading Halt	PRICE SENSITIVE	25/10/22	501.3KB	Share
NTI	New Phase I/II Clinical Trial in Children with PANDAS/PANS	PRICE SENSITIVE	17/10/22	187.64KB	Share
NTI	Executive Change	PRICE SENSITIVE	01/09/22	104.84KB	Share
NTI	Appendix 4E & Annual Report	PRICE SENSITIVE	31/08/22	839KB	Share
NTI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/07/22	337.34KB	Share
NTI	Q&A on NTI164 Breakthrough Clinical Trial Results in ASD	PRICE SENSITIVE	22/07/22	143.91KB	Share
NTI	Reinstatement to Official Quotation	PRICE SENSITIVE	08/07/22	415.41KB	Share
NTI	BREAKTHROUGH RESULTS WITH NTI164 IN PAEDIATRIC ASD	PRICE SENSITIVE	08/07/22	333.24KB	Share
NTI	Extension to Voluntary Suspension	PRICE SENSITIVE	07/07/22	66.46KB	Share
NTI	Suspension from Official Quotation	PRICE SENSITIVE	06/07/22	478.53KB	Share
NTI	Trading Halt	PRICE SENSITIVE	04/07/22	468.39KB	Share
NTI	Preclinical Success with Targeted Combination Therapies	PRICE SENSITIVE	09/06/22	211.17KB	Share
NTI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/04/22	264.61KB	Share
NTI	Successful Landmark Study in Paediatric ASD	PRICE SENSITIVE	05/04/22	242.62KB	Share
NTI	Appointment of Chief Executive Officer	PRICE SENSITIVE	03/03/22	155.56KB	Share
NTI	Appendix 4D and Half Year Accounts	PRICE SENSITIVE	24/02/22	1.64MB	Share
NTI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/22	959.81KB	Share
NTI	Preclinical Success with Targeted Combination Therapies	PRICE SENSITIVE	01/12/21	321.37KB	Share
NTI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/10/21	1.56MB	Share
NTI	Response to ASX Query Letter	PRICE SENSITIVE	14/10/21	295.41KB	Share
NTI	Provisional Patent Lodgements	PRICE SENSITIVE	14/10/21	124.55KB	Share
NTI	Trading Halt	PRICE SENSITIVE	12/10/21	135.33KB	Share
NTI	Appendix 4E and Annual Report	PRICE SENSITIVE	30/08/21	1.02MB	Share
NTI	Quarterly Report and Appendix 4C	PRICE SENSITIVE	30/07/21	365.86KB	Share
NTI	Quarterly Report and Appendix 4C	PRICE SENSITIVE	03/05/21	295.97KB	Share
NTI	Disclosure Document	PRICE SENSITIVE	15/03/21	401.87KB	Share
NTI	Neurotech Expands License with Dolce Cann Global	PRICE SENSITIVE	02/03/21	82.52KB	Share

NTI Appendix 4E & Annual Report to shareholders
29/08/25	PRICE SENSITIVE	2.03MB	Share
NTI Quarterly Activities/Appendix 4C Cash Flow Report
31/07/25	PRICE SENSITIVE	380.56KB	Share
NTI Positive Human PK Study Results for NTI164
02/06/25	PRICE SENSITIVE	123.18KB	Share
NTI NTI164 Preclinical Toxicology Studies Update
05/05/25	PRICE SENSITIVE	112.86KB	Share
NTI Quarterly Activities/Appendix 4C Cash Flow Report
28/04/25	PRICE SENSITIVE	314.41KB	Share
NTI Appendix 4D and Half Year Accounts
27/02/25	PRICE SENSITIVE	1006.37KB	Share
NTI Positive Opinion on OMPD for NTI164 in Europe
27/02/25	PRICE SENSITIVE	119.43KB	Share
NTI NTI Signs Development Agreement for Cannabinoid Therapies
13/02/25	PRICE SENSITIVE	127.25KB	Share
NTI Neurotech Receives $2.44 Million R&D Tax Incentive Refund
31/01/25	PRICE SENSITIVE	134.52KB	Share
NTI Quarterly Activities/Appendix 4C Cash Flow Report
29/01/25	PRICE SENSITIVE	349.64KB	Share
NTI Neurotech Receives US ODD in Rett Syndrome
26/11/24	PRICE SENSITIVE	127.66KB	Share
NTI NTI Receives Ethics Approval to Commence Human PK Study
25/11/24	PRICE SENSITIVE	129.34KB	Share
NTI Positive Genomic Effects of NTI164 in PANDAS/PANS Patients
15/11/24	PRICE SENSITIVE	211KB	Share
NTI Neurotech Appoints Dr Anthony Filippis as MD/CEO
11/11/24	PRICE SENSITIVE	118.54KB	Share
NTI Quarterly Activities/Appendix 4C Cash Flow Report
23/10/24	PRICE SENSITIVE	410.52KB	Share
NTI US FDA Response to Orphan Drug Request in PANDAS/PANS
04/10/24	PRICE SENSITIVE	103.42KB	Share
NTI NTI164 Reverses Immune Dysregulation in PANDAS/PANS Children
09/09/24	PRICE SENSITIVE	160.17KB	Share
NTI Appendix 4E & Annual Report to shareholders
26/08/24	PRICE SENSITIVE	8.99MB	Share
NTI Neurotech Global Partnering and Registration Strategy
12/08/24	PRICE SENSITIVE	185.09KB	Share
NTI Further Significant Improvement in Rett Syndrome Patients
31/07/24	PRICE SENSITIVE	297.53KB	Share
NTI Quarterly Activities/Appendix 4C Cash Flow Report
25/07/24	PRICE SENSITIVE	671.56KB	Share
NTI Phase II/III autism trial shows further benefits
18/07/24	PRICE SENSITIVE	194.28KB	Share
NTI Significant improvement in Autism patients at 12 weeks
10/07/24	PRICE SENSITIVE	347.14KB	Share
NTI Phase I/II Autism Patients Meet 2 Years of NTI164 Treatment
17/06/24	PRICE SENSITIVE	190.62KB	Share
NTI Further clinical benefit at 52 weeks in PANDAS/PANS patients
06/06/24	PRICE SENSITIVE	190.18KB	Share
NTI Rett Syndrome Phase I/II trial shows significant benefits
06/05/24	PRICE SENSITIVE	593.85KB	Share
NTI Trading Halt
03/05/24	PRICE SENSITIVE	140.26KB	Share
NTI Quarterly Activities/Appendix 4C Cash Flow Report
23/04/24	PRICE SENSITIVE	445.81KB	Share
NTI Neurotech Completes $10 Million Capital Raise
17/04/24	PRICE SENSITIVE	193.4KB	Share
NTI Positive Top-Line Rett Syndrome Clinical Trial Results
17/04/24	PRICE SENSITIVE	200.12KB	Share
NTI Phase II/III ASD Trial Successfully Meets Primary Endpoint
17/04/24	PRICE SENSITIVE	361.07KB	Share
NTI Trading Halt
15/04/24	PRICE SENSITIVE	141.44KB	Share
NTI Last Patient Completes Treatment in NTIASD2 Clinical Trial
10/04/24	PRICE SENSITIVE	183.31KB	Share
NTI Rett Syndrome Patients to Receive NTI164 for 52 Weeks
13/03/24	PRICE SENSITIVE	180.94KB	Share
NTI Appendix 4D and Half Year Accounts
27/02/24	PRICE SENSITIVE	814.41KB	Share
NTI PANDAS/PANS Patients Show Continued Clinical Improvement
21/02/24	PRICE SENSITIVE	325.1KB	Share
NTI Neurotech Receives Additional HREC Approval in Autism
13/02/24	PRICE SENSITIVE	114.1KB	Share
NTI NTI Receives HREC Approval for Cerebral Palsy Trial
29/01/24	PRICE SENSITIVE	179.92KB	Share
NTI Quarterly Activities/Appendix 4C Cash Flow Report
24/01/24	PRICE SENSITIVE	583.12KB	Share
NTI Phase II/III Autism Clinical Trial Completes Recruitment
19/12/23	PRICE SENSITIVE	178.77KB	Share
NTI HREC Approval to Extend Phase II/III ASD Trial to Adults
04/12/23	PRICE SENSITIVE	175.52KB	Share
NTI Neurotech Receives $3.17 Million R&D Tax Incentive Refund
14/11/23	PRICE SENSITIVE	105.98KB	Share
NTI Quarterly Activities/Appendix 4C Cash Flow Report
27/10/23	PRICE SENSITIVE	396.35KB	Share
NTI Phase I/II PANDAS/PANS Clinical Trial Meets Primary Endpoint
06/10/23	PRICE SENSITIVE	202.18KB	Share
NTI Trading Halt
04/10/23	PRICE SENSITIVE	503.7KB	Share
NTI Completion of Patient Recruitment in NTIRTT1 Clinical Trial
26/09/23	PRICE SENSITIVE	186.34KB	Share
NTI Last Patient Completes Treatment in NTIPANS1 Clinical Trial
31/08/23	PRICE SENSITIVE	141.88KB	Share
NTI Appendix 4E & Annual Report
30/08/23	PRICE SENSITIVE	1.16MB	Share
NTI First Patient Treated in Rett Syndrome Clinical Trial
01/08/23	PRICE SENSITIVE	181.29KB	Share
NTI Quarterly Activities/Appendix 4C Cash Flow Report
26/07/23	PRICE SENSITIVE	321.97KB	Share
NTI NTI Receives HREC Approval for Rett Syndrome Clinical Trial
10/07/23	PRICE SENSITIVE	213.2KB	Share
NTI NTI Granted 2 Year Extension of Treatment for ASD Patients
31/05/23	PRICE SENSITIVE	188.33KB	Share
NTI NTI granted HREC Approval for PANDAS/PANS Trial Extension
30/05/23	PRICE SENSITIVE	178.8KB	Share
NTI NTI Completes Recruitment in PANDAS/PANS Clinical Trial
03/05/23	PRICE SENSITIVE	138.62KB	Share
NTI Quarterly Activities/Appendix 4C Cash Flow Report
27/04/23	PRICE SENSITIVE	335.94KB	Share
NTI NTI to Launch Phase II Clinical Trial in Rett Syndrome
20/03/23	PRICE SENSITIVE	199.04KB	Share
NTI Phase I/II ASD Clinical Trials Results at 52 Weeks
17/03/23	PRICE SENSITIVE	360.83KB	Share
NTI Trading Halt
15/03/23	PRICE SENSITIVE	499.87KB	Share
NTI Appendix 4D and Half Year Accounts
28/02/23	PRICE SENSITIVE	476.67KB	Share
NTI First Patient Treated in Phase I/II PANDAS/PANS Trial
16/02/23	PRICE SENSITIVE	170.25KB	Share
NTI Approval for Additional Phase I/II ASD Trial Extension
14/02/23	PRICE SENSITIVE	170.33KB	Share
NTI Quarterly Activities/Appendix 4C Cash Flow Report
30/01/23	PRICE SENSITIVE	711.15KB	Share
NTI HREC Approval for Phase I/II PANDAS/PANS Clinical Trial
27/01/23	PRICE SENSITIVE	207.61KB	Share
NTI NTI Granted FDA Pre-IND Meeting for NTI164 in ASD
19/01/23	PRICE SENSITIVE	173.92KB	Share
NTI Disclosure Document
22/12/22	PRICE SENSITIVE	303.07KB	Share
NTI Commencement of Phase II/III ASD Clinical Trial
19/12/22	PRICE SENSITIVE	179.16KB	Share
NTI NTI Receives HREC/TGA Approval for Phase II/III ASD Trial
17/11/22	PRICE SENSITIVE	271.47KB	Share
NTI Neurotech Receives $1.2M R&D Tax Rebate
31/10/22	PRICE SENSITIVE	133.45KB	Share
NTI Quarterly Activities/Appendix 4C Cash Flow Report
31/10/22	PRICE SENSITIVE	340.9KB	Share
NTI Reinstatement to Quotation
28/10/22	PRICE SENSITIVE	409.65KB	Share
NTI Neurotech Completes $9.0M Placement
28/10/22	PRICE SENSITIVE	280.19KB	Share
NTI Suspension From Official Quotation
27/10/22	PRICE SENSITIVE	585.19KB	Share
NTI 20 Week Data Shows Significant Improvement For ASD Children
26/10/22	PRICE SENSITIVE	465.94KB	Share
NTI Trading Halt
25/10/22	PRICE SENSITIVE	501.3KB	Share
NTI New Phase I/II Clinical Trial in Children with PANDAS/PANS
17/10/22	PRICE SENSITIVE	187.64KB	Share
NTI Executive Change
01/09/22	PRICE SENSITIVE	104.84KB	Share
NTI Appendix 4E & Annual Report
31/08/22	PRICE SENSITIVE	839KB	Share
NTI Quarterly Activities/Appendix 4C Cash Flow Report
29/07/22	PRICE SENSITIVE	337.34KB	Share
NTI Q&A on NTI164 Breakthrough Clinical Trial Results in ASD
22/07/22	PRICE SENSITIVE	143.91KB	Share
NTI Reinstatement to Official Quotation
08/07/22	PRICE SENSITIVE	415.41KB	Share
NTI BREAKTHROUGH RESULTS WITH NTI164 IN PAEDIATRIC ASD
08/07/22	PRICE SENSITIVE	333.24KB	Share
NTI Extension to Voluntary Suspension
07/07/22	PRICE SENSITIVE	66.46KB	Share
NTI Suspension from Official Quotation
06/07/22	PRICE SENSITIVE	478.53KB	Share
NTI Trading Halt
04/07/22	PRICE SENSITIVE	468.39KB	Share
NTI Preclinical Success with Targeted Combination Therapies
09/06/22	PRICE SENSITIVE	211.17KB	Share
NTI Quarterly Activities/Appendix 4C Cash Flow Report
29/04/22	PRICE SENSITIVE	264.61KB	Share
NTI Successful Landmark Study in Paediatric ASD
05/04/22	PRICE SENSITIVE	242.62KB	Share
NTI Appointment of Chief Executive Officer
03/03/22	PRICE SENSITIVE	155.56KB	Share
NTI Appendix 4D and Half Year Accounts
24/02/22	PRICE SENSITIVE	1.64MB	Share
NTI Quarterly Activities/Appendix 4C Cash Flow Report
31/01/22	PRICE SENSITIVE	959.81KB	Share
NTI Preclinical Success with Targeted Combination Therapies
01/12/21	PRICE SENSITIVE	321.37KB	Share
NTI Quarterly Activities/Appendix 4C Cash Flow Report
29/10/21	PRICE SENSITIVE	1.56MB	Share
NTI Response to ASX Query Letter
14/10/21	PRICE SENSITIVE	295.41KB	Share
NTI Provisional Patent Lodgements
14/10/21	PRICE SENSITIVE	124.55KB	Share
NTI Trading Halt
12/10/21	PRICE SENSITIVE	135.33KB	Share
NTI Appendix 4E and Annual Report
30/08/21	PRICE SENSITIVE	1.02MB	Share
NTI Quarterly Report and Appendix 4C
30/07/21	PRICE SENSITIVE	365.86KB	Share
NTI Quarterly Report and Appendix 4C
03/05/21	PRICE SENSITIVE	295.97KB	Share
NTI Disclosure Document
15/03/21	PRICE SENSITIVE	401.87KB	Share
NTI Neurotech Expands License with Dolce Cann Global
02/03/21	PRICE SENSITIVE	82.52KB	Share

REFRESH

1 2

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 1.4¢		Change 0.001(7.69%)		Mkt cap ! $14.69M

Open	High	Low	Value	Volume
1.3¢	1.4¢	1.3¢	$4.026K	307.2K

Buyers (Bids)

No.	Vol.	Price($)
1	1917576	1.3¢

Sellers (Offers)

Price($)	Vol.	No.
1.4¢	505017	5

View Market Depth

No.	Vol.	Price($)
1	1917576	0.013
11	3680644	0.012
10	2248075	0.011
8	2120000	0.010
2	159000	0.009

Price($)	Vol.	No.
0.014	505017	5
0.015	1025224	4
0.016	689340	9
0.017	268623	2
0.018	563001	4

Last trade - 16.10pm 29/08/2025 (20 minute delay)

NTI (ASX) Chart

NEUROTECH INTERNATIONAL LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories